News

The approval of the drug is for patients with a confirmed diagnosis of Type 1 Gaucher disease associated with at least one of the following – splenomegaly, hepatomegaly,

The investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without RBV (weight-based),

The company intends to use the facility to manufacture investigational exon skipping therapies for Duchenne muscular dystrophy (DMD). The transaction, which includes about $25m in acquisition costs and

The positive opinion of the CHMP is for both kidney and liver transplant recipients and includes both the de novo transplant and switch settings, as well as for

The patent, titled ‘Reduced Size Self-Delivering RNAi Compounds’, broadly covers both the composition and methods of use of RXi’s self-delivering platform technology. The patent, once issued, will be

NCCN ORP vice president Dr Diane Paul said that the ongoing collaboration between the NCCN ORP and Boehringer Ingelheim Pharmaceuticals is a true testament to the advancement of

The randomized, double blind, multicenter, parallel-group Phase III trial is designed to evaluate the safety and efficacy of DCVAC/PCa as an add-on therapy to 1st line standard of

The exclusive license grants GCA Therapeutics the right to clinically develop and commercialize Leptin Products in China, exclusive of Hong Kong, and Taiwan. The company said that a

The company said that EscharEx is based on its patented proteolytic enzyme technology. About 72 patients are expected to be enrolled in the prospective, randomized, controlled, multicenter Phase